SciELO - Scientific Electronic Library Online

 
vol.19 issue1-2Direct anticoagulants in patients with atrial fibrillation. From clinical trials to real-world recordsAtrial Flutter in a Patient with a Two-chamber Pacemaker. What is the mechanism? author indexsubject indexarticles search
Home Pagealphabetic serial listing  

Services on Demand

Journal

Article

Indicators

Related links

  • Have no similar articlesSimilars in SciELO

Share


Revista Costarricense de Cardiología

Print version ISSN 1409-4142

Abstract

CHAVES SOLANO, Luis Alejandro  and  BOLANOS RODRIGUEZ, Hernán. Cardiovascular Safety of Oral Antidiabetics. Rev. costarric. cardiol [online]. 2017, vol.19, n.1-2, pp.13-17. ISSN 1409-4142.

Cardiovascular Safety of Oral Antidiabetics

Diabetes Mellitus type 2 (DM-2) is an equivalent of cardiovascular risk. There is a wide variety of drugs for the glycemic control in patients with DM-2, which have differences in their cardiovascular profile, some have shown a benefit in reducing the risk of cardiovascular events, others have a neutral effect, and in the case of other drugs such as sulfonylurea and thiazolidinedione, there are doubts about their cardiovascular safety. Being DM-2 an equivalent of coronary risk, it is essential to consider the cardiovascular risk profile of these medicines when starting any of these drugs and not only their effectiveness in controlling glycaemia levels. The objective of this review is to comment on the most recent studies evaluating cardiovascular risk with the use of different oral antidiabetics.

Keywords : diabetes mellitus type 2; cardiovascular risk; glycemia; antidiabetic.

        · abstract in Spanish     · text in Spanish     · Spanish ( pdf )